Business Context and Reporting Period
Company: Geron Corporation
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 2004
Business Overview: Geron is a biopharmaceutical company focused on developing therapeutic and diagnostic products for cancer based on telomerase technology and cell-based therapeutics using human embryonic stem cell (hESC) technology. The company has no approved products on the market and relies on research and development funding.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sep 30, 2004 | Nine Months Ended Sep 30, 2004 | Nine Months Ended Sep 30, 2003 |
|---|---|---|---|
| Total Revenues | $101 | $715 | $1,019 |
| Net Loss | $(10,302) | $(70,930) | $(22,327) |
| Net Loss Per Share (Basic/Diluted) | $(0.23) | $(1.62) | $(0.76) |
| Research & Development Expenses | $8,900 | $22,099 | $19,236 |
| General & Administrative Expenses | $1,676 | $5,120 | $3,717 |
| Cash and Cash Equivalents | $10,185 (Sep 30, 2004) | $12,823 (Dec 31, 2003) | N/A |
| Marketable Securities | $80,015 (Sep 30, 2004) | $96,427 (Dec 31, 2003) | N/A |
| Total Current Assets | $95,128 | $111,808 | N/A |
| Total Current Liabilities | $7,635 | $9,825 | N/A |
| Accumulated Deficit | $(326,596) | $(255,666) | N/A |
Liquidity: As of September 30, 2004, the company held approximately $90.7 million in cash, restricted cash, cash equivalents, and marketable securities. Management estimates these resources, combined with interest income and equipment financing, will fund operations through June 30, 2006.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues for the nine months ended September 30, 2004, decreased to $715,000 from $1,019,000 in the prior year period. This was primarily due to the absence of a $250,000 milestone payment recognized in the third quarter of 2003 and a reduction in collaborative agreement revenues.
- Significant Increase in Net Loss: The net loss for the nine months ended September 30, 2004, widened significantly to $70.9 million from $22.3 million in 2003. This increase was driven by a one-time non-cash charge of $45.2 million for acquired in-process research technology (Merix Bioscience transaction) and increased R&D spending.
- R&D Expense Growth: R&D expenses increased by approximately 15% year-over-year for the nine-month period ($22.1 million vs. $19.2 million), attributed to raw material costs for the manufacture of GRN163L and animal toxicology studies.
- G&A Expense Growth: General and administrative expenses increased by approximately 38% year-over-year ($5.1 million vs. $3.7 million), largely due to increased patent legal costs and expenses related to Sarbanes-Oxley Act compliance.
Guidance, Outlook, and Risks
Outlook and Guidance:
- The company expects to recognize approximately $47,000 in revenue for the remainder of 2004 from existing deferred revenue.
- R&D expenses are expected to increase in the coming year due to manufacturing and testing of telomerase inhibitor compounds and continued clinical trials.
- Management anticipates filing an Investigational New Drug (IND) application for GRN163L by the beginning of the next year, pending successful preclinical studies.
Key Risks and Contingencies:
- Capital Requirements: The company has a history of losses and will require substantial additional capital to fund operations and product development. There is no assurance that future financing will be available on acceptable terms.
- Regulatory Approval: All product candidates are in early stages. Success depends on obtaining regulatory approvals, which are uncertain, lengthy, and expensive.
- Intellectual Property: The company faces risks regarding the enforcement of patents, particularly in Europe regarding human embryonic stem cells, and potential infringement claims.
- hESC Restrictions: Ethical, legal, and social issues surrounding human embryonic stem cells could lead to government restrictions that impair research and development.
Unusual Items:
- Merix Acquisition: In March 2004, the company issued 5,000,000 shares of common stock to Merix Bioscience, Inc. for co-exclusive rights to cancer vaccine technology. The fair value of $45.2 million was expensed immediately as acquired in-process research technology.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $90.7 million cash position to fund operations through mid-2006 given the high burn rate and lack of product revenue.
- Merix Transaction Impact: Confirm the strategic value of the $45.2 million non-cash expense and the timeline for the Merix cancer vaccine to reach clinical trials.
- GRN163L Progress: Monitor the status of preclinical toxicology studies for GRN163L, as the IND filing is contingent on their success.
- Regulatory Environment: Assess potential impacts of changing federal policies regarding human embryonic stem cell research on the company's core hESC programs.
- Patent Litigation: Review the status of ongoing patent interferences and oppositions, particularly those involving the University of Massachusetts and GemVax AS.